BIOCRYST PHARMACEUTICA
7.5000
27-November-24 16:45:00
15 minutes delayed
Stocks
+0.0100
+0.13%
Today's range
7.4250 - 7.6300
ISIN
N/A
Source
NASDAQ
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Sep 2022 07:00:52 By Nasdaq GlobeNewswire
-
BioCryst to Present at Upcoming Investor Conferences
31 Aug 2022 16:01:59 By Nasdaq GlobeNewswire
-
31 Aug 2022 07:00:00 By Nasdaq GlobeNewswire
-
26 Aug 2022 07:00:00 By Nasdaq GlobeNewswire
-
25 Aug 2022 07:00:14 By Nasdaq GlobeNewswire
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
18 Aug 2022 07:00:00 By Nasdaq GlobeNewswire
-
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
04 Aug 2022 07:00:24 By Nasdaq GlobeNewswire
-
BioCryst Resumes Enrollment in BCX9930 Clinical Program
04 Aug 2022 06:58:25 By Nasdaq GlobeNewswire
-
BioCryst to Report Second Quarter 2022 Financial Results on August 4
21 Jul 2022 07:00:44 By Nasdaq GlobeNewswire
-
BioCryst to Present at Upcoming Investor Conference
15 Jul 2022 07:00:23 By Nasdaq GlobeNewswire
-
01 Jul 2022 07:00:00 By Nasdaq GlobeNewswire
-
22 Jun 2022 07:00:02 By Nasdaq GlobeNewswire
-
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
09 Jun 2022 07:00:00 By Nasdaq GlobeNewswire
-
FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
08 Jun 2022 07:00:01 By Nasdaq GlobeNewswire
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
07 Jun 2022 09:00:02 By Nasdaq GlobeNewswire
-
06 Jun 2022 07:00:30 By Nasdaq GlobeNewswire
-
BioCryst to Present at Upcoming Investor Conferences
01 Jun 2022 07:00:15 By Nasdaq GlobeNewswire
-
BioCryst to Present at Upcoming Investor Conferences
06 May 2022 07:00:28 By Nasdaq GlobeNewswire
-
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
05 May 2022 07:00:11 By Nasdaq GlobeNewswire
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 May 2022 16:15:39 By Nasdaq GlobeNewswire